{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T04:37:09Z","timestamp":1768019829820,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Proton pump inhibitors (PPIs) are widely prescribed drugs that have been associated with increased prostate cancer (PCa) cell proliferation in vitro and worse oncological outcomes in vivo. However, data on their influence on PSA levels in the general population are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We extracted individual participant data from the 2001\u20132010 cycles of the National Health and Nutrition Examination Survey (NHANES), in which PSA levels were measured in all male participants aged 40 years or older. The association of PPI use with total PSA levels and free\/total PSA ratio was evaluated through multivariable linear regression analyses, adjusted for potential confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 7366 subjects were included (median age: 53 years; median serum PSA: 0.9 ng\/mL), of whom 746 were receiving PPI treatment at the time of the study. After adjustment for potential confounders, ongoing PPI use was associated with lower total PSA levels (-0.24 ng\/mL, 95%CI: [-0.37,-0.11],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), while no significant association with free\/total PSA ratio was found (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.881). A significant effect modification was observed according to age, with the association being limited to older participants (\u2265\u200960 years) at stratified analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Contrary to the available data in the context of PCa, we found no evidence of increased PSA levels in PPI users with no prostate malignancy. Instead, PPI use was associated with a decrease of total PSA in older adults. This adds knowledge on how PPIs may influence PSA in population-based screening programs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-025-05469-9","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:56:48Z","timestamp":1740099408000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between the use of proton pump inhibitors and serum PSA levels in the general U.S. population"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7550-7023","authenticated-orcid":false,"given":"Fabio","family":"Bioletto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Calleris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi Simone","family":"Aversa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Oderda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Marra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirko","family":"Parasiliti-Caprino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iacopo","family":"Gesmundo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccarda","family":"Granata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezio","family":"Ghigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"5469_CR1","unstructured":"Cornford P, Tilki D, Van den Bergh R et al (2024) EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer. Eur Urol"},{"key":"5469_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/JU.0000000000003491","volume":"210","author":"JT Wei","year":"2023","unstructured":"Wei JT, Barocas D, Carlsson S et al (2023) Early detection of prostate Cancer: AUA\/SUO Guideline Part I: prostate Cancer screening. J Urol 210:46\u201353. https:\/\/doi.org\/10.1097\/JU.0000000000003491","journal-title":"J Urol"},{"key":"5469_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.k3519","volume":"362","author":"D Ilic","year":"2018","unstructured":"Ilic D, Djulbegovic M, Jung JH et al (2018) Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ 362:1\u201312. https:\/\/doi.org\/10.1136\/bmj.k3519","journal-title":"BMJ"},{"key":"5469_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","volume":"76","author":"J Hugosson","year":"2019","unstructured":"Hugosson J, Roobol MJ, M\u00e5nsson M et al (2019) A 16-yr follow-up of the European randomized study of screening for prostate Cancer(figure presented). Eur Urol 76:43\u201351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.009","journal-title":"Eur Urol"},{"key":"5469_CR5","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1007\/s00345-023-04462-4","volume":"41","author":"CV Suartz","year":"2023","unstructured":"Suartz CV, Braz NDSF, dos Anjos GC et al (2023) The use of statins is related to a lower PSA level after endoscopic enucleation of the prostate with holmium laser (HoLEP) for the treatment of BPH. World J Urol 41:2149\u20132154. https:\/\/doi.org\/10.1007\/s00345-023-04462-4","journal-title":"World J Urol"},{"key":"5469_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/s0090-4295(01)01305-x","volume":"58","author":"EP Gelmann","year":"2001","unstructured":"Gelmann EP, Chia D, Pinsky PF et al (2001) Relationship of demographic and clinical factors to free and total prostate-specific antigen. Urology 58:561\u2013566. https:\/\/doi.org\/10.1016\/s0090-4295(01)01305-x","journal-title":"Urology"},{"key":"5469_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.12.005","author":"A Matsukawa","year":"2024","unstructured":"Matsukawa A, Yanagisawa T, Bekku K et al (2024) Comparing the performance of Digital Rectal Examination and prostate-specific Antigen as a screening test for prostate Cancer: a systematic review and Meta-analysis. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2023.12.005","journal-title":"Eur Urol Oncol"},{"key":"5469_CR8","doi-asserted-by":"publisher","unstructured":"Karunasinghe N, Minas TZ, Bao BY et al (2022) Assessment of factors associated with PSA level in prostate cancer cases and controls from three geographical regions. Sci Rep 12. https:\/\/doi.org\/10.1038\/s41598-021-04116-8","DOI":"10.1038\/s41598-021-04116-8"},{"key":"5469_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5056\/jnm.2013.19.1.25","volume":"19","author":"JM Shin","year":"2013","unstructured":"Shin JM, Kim N (2013) Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil 19:25\u201335. https:\/\/doi.org\/10.5056\/jnm.2013.19.1.25","journal-title":"J Neurogastroenterol Motil"},{"key":"5469_CR10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/pds.4702","volume":"28","author":"\u00d3 H\u00e1lfd\u00e1narson","year":"2019","unstructured":"H\u00e1lfd\u00e1narson \u00d3, Fall K, Ogmundsdottir MH et al (2019) Proton pump inhibitor use and risk of breast cancer, prostate cancer, and malignant melanoma: an Icelandic population-based case-control study. Pharmacoepidemiol Drug Saf 28:471\u2013478. https:\/\/doi.org\/10.1002\/pds.4702","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5469_CR11","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41391-020-0248-9","volume":"23","author":"H Goldberg","year":"2020","unstructured":"Goldberg H, Mohsin FK, Saskin R et al (2020) The deleterious association between Proton pump inhibitors and prostate cancer-specific mortality - a population-based cohort study. Prostate Cancer Prostatic Dis 23:622\u2013629. https:\/\/doi.org\/10.1038\/s41391-020-0248-9","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"5469_CR12","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bcpt.13379","volume":"126","author":"\u00d3 H\u00e1lfd\u00e1narson","year":"2020","unstructured":"H\u00e1lfd\u00e1narson \u00d3, Potteg\u00e5rd A, Lund SH et al (2020) Use of proton pump inhibitors and mortality among Icelandic patients with prostate cancer. Basic Clin Pharmacol Toxicol 126:484\u2013491. https:\/\/doi.org\/10.1111\/bcpt.13379","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"5469_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-023-00695-x","author":"W Fukuokaya","year":"2023","unstructured":"Fukuokaya W, Mori K, Yanagisawa T et al (2023) Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-023-00695-x","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"5469_CR14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.canlet.2019.02.028","volume":"449","author":"I Gesmundo","year":"2019","unstructured":"Gesmundo I, Di Blasio L, Banfi D et al (2019) Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1\/2, PI3K\/Akt, GSK-3\u03b2 signaling and inhibition of cellular prostatic acid phosphatase. Cancer Lett 449:252\u2013262. https:\/\/doi.org\/10.1016\/j.canlet.2019.02.028","journal-title":"Cancer Lett"},{"key":"5469_CR15","unstructured":"NHANES - Questionnaires, Datasets, and, Documentation R https:\/\/wwwn.cdc.gov\/nchs\/nhanes\/Default.aspx. Accessed 14 Apr 2024"},{"key":"5469_CR16","doi-asserted-by":"publisher","unstructured":"Leit\u00e3o C, Matos B, Roque F et al (2022) The impact of lifestyle on prostate Cancer: a Road to the Discovery of New biomarkers. J Clin Med 11. https:\/\/doi.org\/10.3390\/jcm11102925","DOI":"10.3390\/jcm11102925"},{"key":"5469_CR17","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1097\/01.ju.0000169255.64518.fb","volume":"174","author":"RD Etzioni","year":"2005","unstructured":"Etzioni RD, Howlader N, Shaw PA et al (2005) Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol 174:877\u2013881. https:\/\/doi.org\/10.1097\/01.ju.0000169255.64518.fb","journal-title":"J Urol"},{"key":"5469_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00345-020-03202-2","volume":"39","author":"PG Knijnik","year":"2021","unstructured":"Knijnik PG, Brum PW, Cachoeira ET et al (2021) The impact of 5-alpha-reductase inhibitors on mortality in a prostate cancer chemoprevention setting: a meta-analysis. World J Urol 39:365\u2013376. https:\/\/doi.org\/10.1007\/s00345-020-03202-2","journal-title":"World J Urol"},{"key":"5469_CR19","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1001\/jamaoncol.2022.1501","volume":"8","author":"L Bj\u00f6rnebo","year":"2022","unstructured":"Bj\u00f6rnebo L, Nordstr\u00f6m T, Discacciati A et al (2022) Association of 5\u03b1-Reductase inhibitors with prostate Cancer mortality. JAMA Oncol 8:1019\u20131026. https:\/\/doi.org\/10.1001\/jamaoncol.2022.1501","journal-title":"JAMA Oncol"},{"key":"5469_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1590\/S1677-5538.IBJU.2023.0578","volume":"50","author":"FPA Glina","year":"2024","unstructured":"Glina FPA, Lopes L, Silva E RS, et al (2024) Do statins decrease testosterone in men? Systematic review and meta-analysis. Int Braz J Urol 50:119\u2013135. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2023.0578","journal-title":"Int Braz J Urol"},{"key":"5469_CR21","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/jnci\/djn362","volume":"100","author":"RJ Hamilton","year":"2008","unstructured":"Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ (2008) The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 100:1511\u20131518. https:\/\/doi.org\/10.1093\/jnci\/djn362","journal-title":"J Natl Cancer Inst"},{"key":"5469_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1001\/jamaoncol.2021.5672","volume":"8","author":"A Vettenranta","year":"2022","unstructured":"Vettenranta A, Murtola TJ, Raitanen J et al (2022) Outcomes of screening for prostate Cancer among men who use statins. JAMA Oncol 8:61\u201368. https:\/\/doi.org\/10.1001\/jamaoncol.2021.5672","journal-title":"JAMA Oncol"},{"key":"5469_CR23","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.euf.2017.03.005","volume":"4","author":"TJ Murtola","year":"2018","unstructured":"Murtola TJ, Vettenranta AM, Talala K et al (2018) Outcomes of prostate-specific Antigen-based prostate Cancer Screening among men using nonsteroidal anti-inflammatory drugs. Eur Urol Focus 4:851\u2013857. https:\/\/doi.org\/10.1016\/j.euf.2017.03.005","journal-title":"Eur Urol Focus"},{"key":"5469_CR24","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1007\/s10620-009-0951-9","volume":"54","author":"RR Kedika","year":"2009","unstructured":"Kedika RR, Souza RF, Spechler SJ (2009) Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci 54:2312\u20132317. https:\/\/doi.org\/10.1007\/s10620-009-0951-9","journal-title":"Dig Dis Sci"},{"key":"5469_CR25","doi-asserted-by":"publisher","unstructured":"Kim HN, Kim JH, Chang Y et al (2021) Gut microbiota composition across normal range prostate-specific antigen levels. J Pers Med 11. https:\/\/doi.org\/10.3390\/jpm11121381","DOI":"10.3390\/jpm11121381"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05469-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05469-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05469-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:03:57Z","timestamp":1767996237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05469-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5469"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05469-9","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"21 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research received approval from the Centers for Disease Control and Prevention Research Ethics Review Board (\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all adult participants (\n                      \n                      ).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}